Business Insights, PHARMACY MARKET

Combatting Future Viral Threats with Vaccine Advances

February 3, 2023

Combatting Future Viral
Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

Spotlight

Cambridge Major Laboratories, Inc.

Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. (AAI|CML) have merged to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation and analytical development, material testing, finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.

OTHER WHITEPAPERS
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

Best Practices for RIM Business Process Automation

whitePaper | December 29, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More
news image

The SwedishDrug Discovery and DevelopmentPipeline 2023

whitePaper | March 23, 2023

Sweden is and should remain a leading life sciences nation. The life sciences industry is one of Sweden’s economic base industries with a signifi cant share of our exports.

Read More
news image

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More
news image

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More
news image

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Read More

Spotlight

Cambridge Major Laboratories, Inc.

Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. (AAI|CML) have merged to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With over 800 employees operating out of seven sites in the US and Europe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation and analytical development, material testing, finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services.

Events